{"name":"Food and Drug Administration (FDA)","slug":"food-and-drug-administration-fda","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Part 1: Spray 2","genericName":"Part 1: Spray 2","slug":"part-1-spray-2","indication":"Other","status":"phase_1"},{"name":"omeprazole/sodium bicarbonate","genericName":"omeprazole/sodium bicarbonate","slug":"omeprazole-sodium-bicarbonate","indication":"Gastroesophageal reflux disease (GERD)","status":"marketed"}]}],"pipeline":[{"name":"Part 1: Spray 2","genericName":"Part 1: Spray 2","slug":"part-1-spray-2","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"omeprazole/sodium bicarbonate","genericName":"omeprazole/sodium bicarbonate","slug":"omeprazole-sodium-bicarbonate","phase":"marketed","mechanism":"Omeprazole inhibits gastric acid secretion by blocking the proton pump in stomach parietal cells, while sodium bicarbonate provides rapid acid neutralization.","indications":["Gastroesophageal reflux disease (GERD)","Peptic ulcer disease","Zollinger-Ellison syndrome","Acid-related dyspepsia"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE1HR2pJQXJsR0JMdGpBX2JINnZaLTk0S3JUd1dsWDVWTVp1WlpDSUs5ZFlzNC03ZTQySzJ4cTZOelRQM2JqUHJiUkxac3llMUE0Tlo0Mlk2ZmZqeXRVSEJ4aUg0TVlYRUFmT2pNVUhsVFQ3MURPelB0amtNNnZBUQ?oc=5","date":"2026-04-08","type":"regulatory","source":"Fierce Pharma","summary":"Regulatory tracker: GSK's Exdensur widens reach with new nod in China - Fierce Pharma","headline":"Regulatory tracker: GSK's Exdensur widens reach with new nod in China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOTmdqS0pqWThKSFVHYUpMTmlvYlRqcEttNXF3dUdNdHZNUGxFa29zTkNRaGFjbmNSX3J6c1ZUZjU2Y0tFSjVIRkZHWklMVEdJUkhucWY2SldwU1lIUFFqMno1ZWRCdGQzWVRUUWJsQ2VJOXBwZDNhYjRhYlNyNmZsckV3SDYzNVpYY1V5UlI3WTJleHc4SkE?oc=5","date":"2026-04-08","type":"regulatory","source":"The Pharma Letter","summary":"Addressing DTC advertising among FDA priorities - The Pharma Letter","headline":"Addressing DTC advertising among FDA priorities","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxORWV5dzZpN1VVN0hiNU5vQnF1Y3R0ZFJscHJWV0RkMWRYYzlJLUsxSk95V0k0OXc3dzd4ZUVjRVBrcWtpTEN5V1lsbi0zb085YzhrdkVtV1FFcUF6YmIyUS11XzZJMkdiQmxESW4tN1MtMF9pUkdnX2xIQ0hxem14REt5eTVfM1JkUFl3NjU4eXRTQ1otdXk4cTZzOXZ1MWI3NUNnMmtMYWY0MmoxeUQ5aTRVQXl3WUtROXgtNXFjUQ?oc=5","date":"2026-04-08","type":"regulatory","source":"Stock Titan","summary":"A new generic version of Monoket reaches market after FDA approval - Stock Titan","headline":"A new generic version of Monoket reaches market after FDA approval","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOcUhFZ0NKaGF4bFJjODR4VEZPN0JJS3Q4a0pYVmc0M29sUlgtbTFWckNySG5McXRCSUZMZ2dPcHhmOEFZai12S2ZhLVFLUEEtMFNMRC1OckRTb3NxbTlpaEFnVWdGQXUyazZnWm1pT3BlODRRM0plY1RyeWFQdmtaRmRpRzRzelZ0eUhhT1F4a0dicDRyUVJwVzZSUQ?oc=5","date":"2026-04-07","type":"regulatory","source":"statnews.com","summary":"FDA backs proposals to entice pharma companies to test, make drugs domestically - statnews.com","headline":"FDA backs proposals to entice pharma companies to test, make drugs domestically","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxObVpiSk9GZEpqSjFsMnl2RkVxMVRJZXZ0dWlxUjBOWEpIMmpaSmxvNUIxNHpHak1RLTNWRG1GZzFUa1NXa1lqUk5IN3RRTmIwQ2lPSDJEaHNpUHhqcTFlN3djSnVyT2d4alFFY2NZRXlvQS1uX1NWZ1ZsRmVTUGRsY1JWSGQtOXZWdlpqT2NOYXFEcU5YYzE3QzdlMW9maWxFYjdiUC16ZXNDNzBuMTFCUHp1Q2ZoTG1zZllXTHFXWjEtSWNK?oc=5","date":"2026-04-07","type":"regulatory","source":"Politico","summary":"FDA seeks more power over drug ads, advisory panels - Politico","headline":"FDA seeks more power over drug ads, advisory panels","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxORUJvaWIwMFczV1p6T3psaDRJWG94R1hoOWRVLXc0TTJUal9fUFhTUnRtbUxzSnFNUnM0T2Z5NElmZ2c4UlQwMlZGeEJVNVFJVVNmd0ZjaUFZU0NQdGhBOVFUODJyQW42elJuajR1YW1LU05kdkYzZUQ5SDJZWXQxUk12b1RrSWd6UGgyWS1MTmVnRldFMnplRHpyUEhMR3VzMVNxdk1oLXF6TUI1WVpIMHZ6MTBTUTcyTDcxVA?oc=5","date":"2026-04-07","type":"regulatory","source":"The Conversation","summary":"Massive eye drop recall reflects ongoing issues with manufacturing and FDA inspection - The Conversation","headline":"Massive eye drop recall reflects ongoing issues with manufacturing and FDA inspection","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOa1M1WUVBUVdkYzUwOXJqUF9mZWdaZTIxNWl3RHh4Z3FJajY5T2NJSm1Nalg0VnM4UjJWcGxWRThvME5NcDZFZU1uZmE1VVY5NjhwZUhNX2FpUC1DbFplemVOM0NPRjlrYmc2SzNtTVJTUG9qNVhXVGh4Z0tTbGh3R21Cek15VWV4SWhnVWRZY1A3V2ZWanZoRUl1ajdaZw?oc=5","date":"2026-04-07","type":"regulatory","source":"The Pharma Letter","summary":"FDA-approved drug manufacturing deals shift to Europe - The Pharma Letter","headline":"FDA-approved drug manufacturing deals shift to Europe","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQX2ZXdzVlY2RjLTNkQjBYZFdfTWVONWp3YU9VZjZzMUZJSm9PXzE5aWVXZVdXeTMzZHZnT2JXNnVfVk16dTBhWUFnVjhtUXBHVlJfOWZMS1NZay1HY1BSeVd2Y3hRSTh4bVB2MGxCd2QyalQySE9JMFFxTVktVmJqb1h4LTlRNmVXYU5hVDZPc3kyZGNlUnBpcURKZS1SVmhxOUtoeGdjRWdvWDQ?oc=5","date":"2026-04-06","type":"regulatory","source":"Yahoo Finance","summary":"Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention - Yahoo Finance","headline":"Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxOVUFJSWgtcnNXNG5JN1JEcjYyWjVJSUh5bjRSSXZSaEszZm5OTVRUelhMRXpTa2ViMGhfVXdXR1lKUlRzMm9lakJPV0tBVjNEVDl4eGw4T2lQWWl2b3hzYmdhTjhrdmJERHFobDBNX0R5bnp4clZBWU92VUs3VlpiTnBYTFpRMDQ1b2J3cklZQ0ZxNVJKVGdUX2otRTUzSFNPelFfZkhpdk43SFVlQndKXzBpZXJxWlJ0TUZmSVdPQWl1SU1rTW5henV4N2FLY3pnX2pmTnpWdzhkZzRTa3ktNWNqcy1Od2hJRFVIdlRR?oc=5","date":"2026-03-30","type":"regulatory","source":"RAPS.org","summary":"Recon: Insilico, Eli Lilly strike $2.75B AI drug development deal; FDA clears Butterfly Network’s AI ultrasound pregnancy tool - RAPS.org","headline":"Recon: Insilico, Eli Lilly strike $2.75B AI drug development deal; FDA clears Butterfly Network’s AI ultrasound pregnanc","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxON0lxZnJ1djZPYUh2OXE5amZval9nbG14a3ExeDZ0WnpJaElKTEdNazdJazBVOTlaN29CLVE1N3A2S3VOY0JzMl9pNlhZSGJKRloxVnBXSi1aQlpUd1NJWU9wSzdGamJTUmZUTm43RU9fdjlva0w1U3Ntbk5SRFlESk9zM1pXajVEVWhveVVPaVh4R2JTdzYtNTJ5RU5zT0ItclVtTEVR?oc=5","date":"2026-03-18","type":"regulatory","source":"fda.gov","summary":"Implementing Alternative Methods - fda.gov","headline":"Implementing Alternative Methods","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgJBVV95cUxQeXM5dzR5YVFhUXVmUkxCS0xlZzd5NDFYRXhtV0NqTUNONEhQN0ZpRXNhNjdxeE9uNzRkVnFQanM2cXJ6a1R5bWxPSFUwN204cm5CYmZ5UnduMV9Sd3pSQzlNazdKb0h2M0pvaEp5UGZmcjZ2dE84amZGNFZENWFUZ25fNVA3cFV3RHpmVXBCRXRPMl9QVDd3YXlNcWVhMllTbGtlN3BVWlV4SUtMWTllTWlfNnF6czkxcHdhc1JNb1JMU2FTTzhSc05FTXlpMjhZVEIwM0xwQnpZNlVrZzl4d0V2NkE2RFpTMjRCOHBXQS1qVlRVZkhMQnlaYzVQeEZMUXRVTnpXLUZ3RU1tUXR0bGhXN0VIYmQtZ3pOLWFsMlFWQ3czOEY1NFE4N3c2WU1lOEE?oc=5","date":"2026-03-12","type":"regulatory","source":"PR Newswire","summary":"Pierre Fabre Pharmaceuticals Announces Type A Meeting Agreed with U.S. Food and Drug Administration (FDA) for Tabelecleucel Biologic License Application (BLA) - PR Newswire","headline":"Pierre Fabre Pharmaceuticals Announces Type A Meeting Agreed with U.S. Food and Drug Administration (FDA) for Tabelecleu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTFBBSXdJdGxWV2VLSktaOVpQeGFBMUV2cHh2Q1NveTFXQk01cXE5M19oZ2p4TEtxX0dLcVY3eUFwZTBGNE1vUEFaVXhwenVDVmZGSTJ1QzFKOUFPcjJyM21TU2d3R2ZaQ29UdXVaMGFXYXZjUQ?oc=5","date":"2025-09-09","type":"regulatory","source":"HHS.gov","summary":"HHS, FDA to Require Full Safety Disclosures in Drug Ads - HHS.gov","headline":"HHS, FDA to Require Full Safety Disclosures in Drug Ads","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":1,"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}